Apalutamide

(Erleada®)

Erleada®

Drug updated on 11/16/2023

Dosage FormTablet (oral; 60 mg, 240 mg)
Drug ClassAndrogen receptor inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of patients with metastatic castration-sensitive prostate cancer.
  • For the treatment of patients with non-metastatic castration-resistant prostate cancer.

Product Monograph / Prescribing Information

Document TitleYearSource
Erleada (apalutamide) Prescribing Information.2023Janssen Biotech

Systematic Reviews / Meta-Analyses

Document TitleYearSource
A systematic review and meta-analysis on overall survival, failure-free survival and safety outcomes in patients with metastatic hormone-sensitive prostate cancer treated with new anti-androgens.2023Anti-Cancer Drugs
Immune checkpoint inhibitor- and phosphatidylinositol-3-kinase inhibitor-related diabetes induced by antineoplastic drugs: two case reports and a literature review. 2023Frontiers in Endocrinology
Systemic therapies for high-volume metastatic hormone-sensitive prostate cancer: a network meta-analysis. 2023Acta Oncologica
Does Research from Clinical Trials in Metastatic Hormone-sensitive Prostate Cancer Treatment Translate into Access to Treatments for Patients in the "Real World"? A Systematic Review.2023European Urology Oncology
The optimal upfront therapy in metastatic hormone-sensitive prostate cancer: A network meta-analysis. 2023Journal of Cancer Research and Therapeutics
Association of Second-generation Antiandrogens With Cognitive and Functional Toxic Effects in Randomized Clinical Trials: A Systematic Review and Meta-analysis. 2023The optimal upfront therapy in metastatic hormone-sensitive prostate cancer: A network meta-analysis.
Comparative efficacy of second-generation androgen receptor inhibitors for treating prostate cancer: A systematic review and network meta-analysis. 2023Frontiers in Endocrinology
First-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate Cancer: A Living Systematic Review and Network Meta-analysis. 2023JAMA Oncology
The efficacy and adverse events of conventional and second-generation androgen receptor inhibitors for castration-resistant prostate cancer: A network meta-analysis2023Frontiers in Endocrinology
Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. 2023Prostate Cancer and Prostatic Diseases
A meta-analysis on overall survival and safety outcomes in patients with nonmetastatic castration-resistant prostate cancer treated with novel hormonal agents.2022Anti-Cancer Drugs
Androgen receptor signaling inhibitors in addition to docetaxel with androgen deprivation therapy for metastatic hormone- sensitive prostate cancer: a systematic review and meta-analysis.2022European Urology
Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. 2021Prostate Cancer and Prostatic Diseases
Comparison of systemic treatments for metastatic castration-sensitive prostate cancer: a systematic review and network meta-analysis. 2021JAMA Oncology
Seizures and neuropsychiatric toxicity in patients with non-metastatic crpc treated with new antiandrogens: systematic review and meta-analysis. 2021Oncology Research and Treatment
Overall survival after systemic treatment in high-volume versus low-volume metastatic hormone-sensitive prostate cancer: systematic review and network meta-analysis. 2021European Urology Focus
Neoadjuvant treatment with androgen receptor signaling inhibitors prior to radical prostatectomy: a systematic review. 2021World Journal of Urology
Comparison of treatments for nonmetastatic castration-resistant prostate cancer: matching-adjusted indirect comparison and network meta-analysis. 2021Journal of the National Cancer Institute
Apalutamide, darolutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer: a meta-analysis. 2021Future Oncology
Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer.2021NICE
Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer.2021NICE
Systemic therapies for metastatic hormone-sensitive prostate cancer: network meta-analysis. 2021BJU International
Risk of cardiovascular toxicities and hypertension in nonmetastatic castration-resistant prostate cancer patients treated with novel hormonal agents: a systematic review and meta-analysis. 2021Expert Opinion on Drug Metabolism & Toxicology
Comparative efficacy of apalutamide darolutamide and enzalutamide for treatment of non-metastatic castrate-resistant prostate cancer: a systematic review and network meta-analysis.2020Urologic Oncology
Systemic management for nonmetastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.2020American Journal of Clinical Oncology
A systematic review and network meta-analysis of novel androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer.2020Clinical Genitourinary Cancer
Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.2020International Journal of Clinical Oncology
First-line systemic therapy for metastatic castration-sensitive prostate cancer: an updated systematic review with novel findings. 2020Critical Reviews in Oncology/Hematology
Final clinical guidance report: apalutamide (Erleada) for metastatic castration-sensitive prostate cancer.2020CADTH
Antiandrogen therapies for nonmetastatic castration-resistant prostate cancer: effectiveness and value. 2018ICER
Final clinical guidance report: apalutamide (Erleada) for castration-resistant prostate cancer. 2018CADTH
Management of non-metastatic castrate-resistant prostate cancer: a systematic review. 2018Cancer Treatment Reviews

Clinical Practice Guidelines